Hantavirus — questions, answered

Generally, no. Most hantavirus species — including Sin Nombre virus, Puumala, Hantaan, and Seoul — are transmitted only through contact with infected rodents or their droppings, urine, and saliva. The single documented exception is the Andes virus (ANDV), found primarily in Argentina and Chile. Andes virus has been linked to limited person-to-person transmission, but only in cases of close, prolonged contact (e.g., household members or healthcare workers without protection). The MV Hondius cluster involves Andes virus, which is why contact tracing is being conducted internationally despite the rarity of human-to-human spread.

The MV Hondius 2026 cluster is the first documented hantavirus outbreak linked to cruise ship travel, but the ship environment was not itself the source of transmission. Hantavirus does not spread easily from person to person — the source was an index case who had spent four months in Andes virus-endemic areas of Argentina, Chile, and Uruguay before boarding. Andes virus is the only hantavirus strain with documented (but limited) person-to-person transmission, requiring prolonged close contact. WHO and ECDC assessed the risk to the general public from the MV Hondius cluster as 'low' to 'very low'. The episode demonstrates that travelers returning from Andes-endemic South American regions within 8 weeks of symptoms should disclose that travel history to clinicians immediately.

Hantavirus incubation typically ranges from 1 to 8 weeks after exposure, with most cases presenting symptoms 2-4 weeks after contact (CDC). This long incubation is one reason WHO continues active monitoring of MV Hondius passengers and contacts: passengers who disembarked at Saint Helena on 24 April 2026 returned home to multiple countries, so new cases linked to the cluster could emerge as late as mid-June 2026. The live country list and contact tracing scope are shown on the homepage.

Hantavirus spreads primarily from rodents to humans through four main routes: (1) Inhalation of aerosolized urine, droppings, or saliva from infected rodents — the most common route, especially in poorly ventilated enclosed spaces like cabins, garages, sheds, and barns. (2) Direct contact with rodents, their excreta, or contaminated surfaces, especially with broken skin or mucous membranes. (3) Bite from an infected rodent (rare). (4) Eating food contaminated with rodent excreta. Andes virus also has rare documented person-to-person transmission, requiring close prolonged contact (e.g., household members, healthcare workers without PPE). Hantavirus is not transmitted by mosquitoes, ticks, or other arthropods.

Measles is one of the most contagious infectious diseases known. It spreads through the air via tiny respiratory aerosols and droplets released when an infected person coughs, sneezes, or breathes. The virus can survive in the air and on surfaces for up to 2 hours after an infected person has left a room — meaning you can catch measles without direct contact. The basic reproduction number (R₀) is 12–18: each infectious person can infect 12 to 18 unvaccinated contacts in a susceptible population. An infected person is contagious from about 4 days before their rash appears through 4 days after — roughly 8 days total, often before they know they are sick. Measles has no animal reservoir, which means it can only survive by continuously infecting people. This makes herd immunity — achieved through ≥95% two-dose MMR vaccination — the only sustainable way to stop transmission.

Ebola is NOT airborne. Human-to-human transmission requires direct contact with the blood or body fluids (saliva, vomit, urine, feces, breast milk, semen) of a symptomatic or deceased infected person, or with surfaces and objects contaminated by those fluids. Traditional burial practices involving contact with the deceased are a well-documented transmission route, as is nosocomial spread in healthcare settings lacking adequate infection control. The virus can also persist in semen for months after recovery, making sexual transmission possible. Animal-to-human spillover is believed to originate from fruit bats (Pteropodidae) and infected non-human primates.

Smallpox spread almost exclusively person-to-person through respiratory droplets and direct contact with skin lesions, and was highly contagious with a basic reproduction number (R0) of 5-7. Mpox is less transmissible: clade IIb (2022 outbreak) spread primarily through close physical and sexual contact, with an estimated R0 of 1.1-2.4 in the MSM community. Mpox also has a zoonotic reservoir (rodents, primates), meaning it can re-enter the human population from animals — unlike smallpox, which had no animal reservoir.

The primary route is contact with the multimammate rat (Mastomys natalensis) — specifically its urine, faeces, or saliva — or by handling and consuming infected rats. Human-to-human transmission occurs through direct contact with blood, urine, faeces, vomit, or other bodily fluids of an infected person. Lassa fever is NOT airborne; casual contact poses minimal risk. Healthcare workers are at risk without adequate PPE. Sexual transmission is documented during convalescence, as the virus persists in semen for up to three months.

Hantavirus is not airborne in the way COVID-19 or measles are. It is transmitted through aerosols generated when dried rodent excreta (urine, droppings, saliva) become disturbed and suspended in the air locally — for example when sweeping a rodent-infested cabin or vacuuming dry droppings. This means the 'airborne' fraction of transmission is short-range and tied to specific environmental conditions, not breathable in shared rooms over time the way respiratory pathogens are. The Andes virus exception involves close prolonged contact between humans, also not classical respiratory airborne transmission. Standard ventilation (open windows for 30+ minutes before entering a closed cabin) effectively reduces risk.

Lassa fever can spread person-to-person, but is far less contagious than diseases like measles or COVID-19. Transmission requires direct contact with the blood, urine, faeces, vomit, or other bodily fluids of an infected person — casual contact, sharing air, or coughing do not spread the virus. Healthcare workers who treat Lassa patients without adequate PPE are at significant risk. Sexual transmission is documented during convalescence because the virus persists in semen for up to three months. Large household clusters are uncommon; most secondary cases occur in healthcare settings without strict infection control. This is in contrast to Ebola, which has caused much larger nosocomial clusters.

Mpox is not classified as a traditional sexually transmitted infection (STI), but sexual contact is an efficient transmission route. During the 2022 clade IIb global outbreak, the majority of cases in high-income countries involved men who have sex with men (MSM), transmitted through close skin-to-skin contact during sex. The virus spreads via direct contact with lesions, rash, or body fluids — circumstances common during sexual activity. However, mpox also transmits through non-sexual close contact (household, healthcare settings), distinguishing it from classic STIs.

A person with measles is contagious from approximately 4 days before the rash appears through 4 days after rash onset — a total infectious window of about 8 days. This means an infected person is spreading measles before they even know they have it, since the rash does not appear until the disease has been progressing for several days. During the prodromal phase (before the rash), the only symptoms are fever, cough, runny nose, and red eyes — easily mistaken for a common cold or flu. This pre-rash contagiousness is one of the main reasons measles outbreaks are so hard to contain: by the time someone is diagnosed, they may have already exposed many others. People with measles should be isolated from others from 4 days before rash onset through 4 days after rash onset, per CDC guidelines.

Yes. China reports the world's highest annual burden of hantavirus disease, with roughly 10,000 to 20,000 cases of hemorrhagic fever with renal syndrome (HFRS) each year — mostly caused by Hantaan virus and Seoul virus carried by Apodemus agrarius (striped field mouse) and Rattus norvegicus (brown rat) respectively. Provinces with the highest incidence are Shaanxi, Heilongjiang, Shandong, and Liaoning. The 2025 epidemiological report from China CDC showed continued decline from 1980s peaks (which exceeded 100,000 cases per year) thanks to rodent control programs and the domestic inactivated bivalent vaccine Hantavax (Hantaan + Seoul, licensed in China since 1994). The MV Hondius 2026 outbreak involves Andes virus — a New World strain unrelated to Chinese-endemic strains — and is therefore epidemiologically separate from China's ongoing HFRS background activity. Travelers to China face very low hantavirus risk in urban areas; rural cabins and grain storage with active rodent infestation are the historical exposure setting.

No. Hantavirus is not an identified health risk for Hajj or Umrah pilgrims. Saudi Arabia's Arabian Peninsula geography does not support endemic hantavirus circulation: no rodent species carrying pathogenic hantavirus strains (such as Andes virus, Sin Nombre virus, or Puumala virus) are established in the region. WHO's Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among zoonotic disease priorities for Saudi Arabia or neighboring Gulf states. The MV Hondius 2026 cluster does not involve any Saudi Arabian, Gulf, or Levantine passengers among confirmed cases or priority contact-tracing lists as of May 2026. For Hajj health priorities, WHO and the Saudi Ministry of Health focus on meningococcal meningitis (ACWY vaccine mandatory for many nationalities), MERS-CoV (Middle East Respiratory Syndrome), respiratory infections, heat illness, and food safety. No hantavirus-specific measures are required or recommended for travel to Saudi Arabia or any other country in the Middle East and North Africa region.

Hantavirus risk follows rodent population cycles, which vary by region and species. United States (Sin Nombre virus): cases peak in late spring and early summer (May–July) in the US Southwest, correlating with the deer mouse (Peromyscus maniculatus) breeding season that drives rodents into human structures — cabins, barns, and outbuildings closed over winter. The CDC notes that 'spring cleaning' of rural cabins without proper precautions (sweeping dry droppings without a mask) is a recurring documented exposure scenario. Scandinavia and Northern Europe (Puumala virus): cases spike in autumn and winter when bank voles (Myodes glareolus) move into homes and farm buildings. Outbreak years correlate with vole population boom cycles every 3–4 years. South America (Andes virus): year-round transmission with no sharply defined peak; cases rise slightly in autumn and winter in Argentina and Chile when cooler temperatures push rodents indoors. The MV Hondius index case was exposed between November 2025 and April 2026 — an autumn-to-early-autumn window in the Southern Hemisphere. Traveler advice: high-risk activities in endemic regions (wilderness camping, cleaning rural structures) carry elevated risk during local rodent breeding seasons. Check CDC country-specific travel advisories before visiting endemic areas.

Travel to South America remains safe for most itineraries, but travelers should understand the geographically specific risk from Andes virus. Risk zones are rural areas — particularly Patagonia and the Four Corners region of Argentina (Neuquén, Río Negro, Chubut, Santa Cruz provinces), southern Chile (Regions X–XIV), and parts of Uruguay — not major cities such as Buenos Aires, Santiago, or Montevideo. WHO has not issued a travel advisory against South America for hantavirus. The 2026 MV Hondius cluster arose from a single index case who spent four months in these rural endemic areas. Recommended precautions: avoid sleeping or spending extended time in rodent-infested rural huts, barns, or storage buildings; if camping, use elevated sleeping platforms away from field mouse habitat; never sweep rodent droppings in enclosed spaces — wet them first with 1:10 bleach solution before cleaning. Travelers developing fever, intense muscle pain, and respiratory difficulty within 8 weeks of returning from rural endemic areas in Argentina or Chile should disclose that travel history to emergency physicians immediately.

Hantavirus species are distributed globally, with regional specialization. Americas: Sin Nombre virus (USA Four Corners region — NM, AZ, CO, UT — also CA, OR, WA), Andes virus (Argentina, Chile, Uruguay), Bayou and Black Creek Canal viruses (Gulf states USA), Choclo virus (Panama). Europe: Puumala virus (Scandinavia, Baltic, Russia, Germany, France, Belgium, limited northern Italy), Dobrava-Belgrade (Balkans). Asia: Hantaan virus (China, Korea), Seoul virus (worldwide via Norway rats), Amur virus (eastern Russia). Africa: Sangassou virus (Guinea — limited human disease known). The MV Hondius outbreak involves Andes virus from South America. The ship is currently off Cape Verde (West Africa, no endemic hantavirus) en route to the Canary Islands, Spain.

Italy has no documented autochthonous (locally acquired) cases of hantavirus disease. Puumala virus (PUUV) — a milder hantavirus species causing HFRS — has limited presence in some northern alpine regions (Trentino-Alto Adige, Friuli-Venezia Giulia) but no recent human cases. ECDC assesses the risk for the general European population from the MV Hondius outbreak as 'very low'. The Italian Ministry of Health has nonetheless reinforced surveillance for travelers returning from South America during the relevant exposure window.

There is no documented endemic hantavirus circulation in the Arabian Peninsula (Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Yemen) or in the Levant (Jordan, Lebanon, Syria, Iraq, Palestine, Israel). Limited serological surveys in Egypt and Turkey have detected hantavirus antibodies in commensal rodents (likely Seoul virus from Rattus norvegicus), but no clinically significant human cases linked to those reservoirs have been reported. The WHO Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among priority emerging zoonoses for the region. The MV Hondius 2026 outbreak does not currently involve any Middle Eastern country in confirmed-case or contact-tracing lists. Risk to residents and travelers within the region remains very low, including for pilgrims attending Hajj or Umrah in Saudi Arabia, where the primary health concerns remain meningococcal disease, MERS-CoV, respiratory infections, and heat illness.

Yes — measles is back in the United States and in several other countries in 2026. The US is experiencing its largest measles resurgence in decades: over 2,104 confirmed cases were reported to the CDC by mid-2026, surpassing every annual total since before the disease was declared eliminated in 2000. The outbreak is driven entirely by communities with low two-dose MMR vaccination coverage, not by a change in the virus itself. The measles virus (Measles morbillivirus) is genetically unchanged and the MMR vaccine remains highly effective (97% with two doses). States most affected include Texas, Montana, and others where pockets of unvaccinated individuals allowed the virus to sustain chains of transmission. Globally, WHO reports active outbreaks in Romania, Italy, the Democratic Republic of Congo, and several countries in sub-Saharan Africa and Southeast Asia in 2025–2026. Measles is not 'back' as an endemic pathogen in the USA — elimination status is maintained as long as no continuous year-round chain of domestic transmission is established — but the current outbreak is a serious public-health warning about the consequences of falling vaccination rates.

Nigeria has the highest reported burden, with thousands of cases annually tracked by the Nigeria Centre for Disease Control (NCDC). Sierra Leone, Liberia, and Guinea are also highly endemic. Sporadic cases have occurred in Mali, Ivory Coast, and Benin. International importation has been recorded in Europe and North America among returning travellers. The WHO regularly issues Disease Outbreak News alerts for Nigeria, with peak transmission typically between January and April.

Yes. The United States is experiencing a significant measles resurgence in 2025–2026, with case counts reaching levels not seen since 2019. Outbreaks have been concentrated in communities with low MMR vaccination rates — particularly among unvaccinated children and adults in states including Texas, Montana, and others. Measles was declared eliminated from the USA in 2000, meaning there is no longer sustained year-round transmission; however, outbreaks still occur when unvaccinated travelers import the virus and it spreads through under-immunized pockets of the population. The CDC monitors all cases and recommends two-dose MMR vaccination as the primary prevention measure. International travel to countries with active measles transmission increases exposure risk for unvaccinated individuals. Parents should confirm their children have received two MMR doses on schedule; adults who are unsure of their vaccination history should consult a physician.

The MV Hondius hantavirus cluster (Andes virus, 2026) spans multiple countries across four continents. Countries with confirmed or suspected patients receiving treatment: Netherlands (two confirmed deaths; ship is Dutch-flagged), Germany (patient transferred by medical evacuation), Switzerland (patient hospitalized), South Africa (patient transferred by medical evacuation), and Saint Helena (30 passengers disembarked 24 April 2026). Countries with active contact-tracing operations for passengers or crew who traveled onward: United States (17 American nationals were aboard), United Kingdom, France, Spain (final port call scheduled Las Palmas, Canary Islands, approximately 11 May 2026), Canada, Singapore. Countries involved in the index case's pre-embarkation travel (Andes virus exposure corridor): Argentina (Ushuaia departure port; index case traveled through southern Argentina for four months), Chile, Uruguay. WHO Disease Outbreak News DON599 covers 23 nationalities aboard. ECDC rates the risk to EU/EEA general public as 'very low'.

Ebola virus disease has a historical case-fatality rate of 25-90% depending on strain, with Bundibugyo ebolavirus — the strain driving the active 2026 outbreak in the Democratic Republic of the Congo and Uganda — historically around 25-40%. Per the WHO Situation Report of 18 May 2026, the outbreak had recorded 528 reported cases (2 lab-confirmed in Uganda, 526 under investigation) and 132 deaths, with 668 contacts identified. No vaccine or monoclonal antibody therapy is currently approved for the Bundibugyo strain, unlike Zaire ebolavirus which has Ervebo and two approved antibody treatments. WHO declared the outbreak a Public Health Emergency of International Concern on 18 May 2026.

Mortality varies sharply by virus species. Andes virus and Sin Nombre virus, which cause hantavirus pulmonary syndrome (HPS), have a historical case fatality rate (CFR) of 30-40%. The Eurasian variants causing hemorrhagic fever with renal syndrome (HFRS) — Puumala, Hantaan, Seoul — have lower CFR: Puumala 0.1-1%, Seoul ~1-2%, Hantaan 5-15%. The MV Hondius cluster involves Andes virus, the most lethal strain. The current CFR for this cluster is shown on the homepage Deaths KPI (deaths divided by confirmed cases) and updates hourly as new data is reported. There is no specific antiviral treatment; supportive intensive care (oxygen, ventilation, ECMO) is the standard of care and improves outcomes when initiated early.

No. Mpox is substantially less dangerous than smallpox. Smallpox had a case fatality rate of approximately 30% and caused disfigurement in survivors. Mpox clade II (responsible for the 2022-2024 global outbreak) has a fatality rate below 1% in high-income settings. Mpox clade I, circulating in Central Africa, carries a higher fatality rate of 1-10%, historically higher in children. Smallpox was eradicated globally in 1980; mpox continues to circulate in animal reservoirs and spreads to humans.

The overall case fatality rate (CFR) is approximately 1%, reflecting the high proportion of mild or asymptomatic cases. In hospitalised patients — who represent the severe end of the spectrum — the CFR rises to 15-25%. Lassa fever accounts for an estimated 5,000 deaths per year across West Africa. Pregnant women in the third trimester face especially high risk: foetal mortality approaches 80%, and maternal mortality is also significantly elevated.

Almost certainly not, based on current evidence. WHO Director-General publicly stated on 7 May 2026 that the MV Hondius cluster is 'not the next COVID'. Three structural reasons: (1) Hantavirus does not transmit efficiently between humans — Andes virus, the only strain with documented person-to-person spread, requires close prolonged contact, with effective R0 well below 1 in human chains. (2) The natural reservoir (specific rodent species) is geographically constrained, so sustained spread requires the rodents, not just sick humans. (3) High mortality (30-40%) paradoxically slows spread by killing or hospitalizing hosts before they can infect others — the classic 'too lethal to spread' dynamic. Polymarket traders agree: the 'Hantavirus pandemic 2026' question, after spiking to 38% on initial alarm, has settled at 9% with $2.2M traded. Continued vigilance is warranted given the 6-week incubation, but pandemic is highly improbable.

Isolation requirements differ by hantavirus species. For most variants (Sin Nombre, Puumala, Hantaan, Seoul): standard contact precautions are sufficient because there is no documented human-to-human transmission. Healthcare workers should use standard PPE (gloves, surgical mask, eye protection) during procedures that generate aerosols from bodily fluids. For Andes virus — the strain in the MV Hondius 2026 cluster — WHO and ECDC recommend upgraded droplet-plus-contact precautions given the documented, albeit rare, human-to-human transmission risk. This means N95 or equivalent respirator, gown, gloves, and eye shield for direct patient care. The CDC advises airborne precautions (negative-pressure room + N95) when performing high-aerosol procedures such as intubation or bronchoscopy on suspected HPS patients. In the MV Hondius outbreak, WHO distributed 2,500 diagnostic kits and issued specific healthcare-worker guidance emphasizing that Andes virus requires a heightened precautionary approach. Household contacts of Andes virus patients should self-monitor for symptoms for 8 weeks from last exposure; they do not require medical isolation unless symptomatic.

CDC prevention guidance focuses on minimizing rodent exposure. The standard recommendations are: (1) Seal openings >¼ inch around homes, sheds, and cabins to prevent rodent entry. (2) Trap rodents using snap traps in problem areas; do not use poison alone (carcasses must still be removed safely). (3) Before entering long-closed buildings (cabins, garages, storage sheds), open doors and windows for at least 30 minutes to ventilate. (4) Wet down dust and droppings with a bleach solution (1:10) before cleaning; never sweep or vacuum dry rodent waste, as this aerosolizes virus particles. (5) Wear rubber/latex gloves and an N95 respirator when handling potential rodent contamination. (6) Store food in rodent-proof containers. For travelers to endemic regions, avoid sleeping in rodent-infested cabins or tents.

Prevention focuses on reducing contact with the multimammate rat (Mastomys natalensis), the primary animal reservoir. Key measures recommended by the WHO and CDC include: (1) Store food in rodent-proof containers and dispose of garbage away from the home. (2) Keep homes clean and seal entry points to discourage rats. (3) Avoid contact with rodents, their nests, urine, or faeces. (4) Healthcare workers must use appropriate personal protective equipment (PPE) — gloves, gowns, masks — when caring for suspected or confirmed Lassa fever patients, and follow strict infection control protocols. (5) Community education in endemic areas (Nigeria, Sierra Leone, Liberia, Guinea) on the risks of handling or consuming rats. There is currently no approved vaccine for Lassa fever, though multiple candidates are in clinical development under CEPI funding.

The MMR (measles-mumps-rubella) vaccine is highly effective. A single dose provides approximately 93% protection against measles; two doses provide approximately 97% protection. The two-dose schedule — first at 12–15 months, second at 4–6 years — is the global standard recommended by WHO and CDC and is why measles was declared eliminated from the USA in 2000. Protection from two doses is generally lifelong for the vast majority of vaccinated people. Adults born before 1957 are presumed immune from prior natural infection. Adults born in 1957 or later who haven't had measles or received two vaccine doses should get vaccinated. The 2025–2026 USA resurgence is driven entirely by communities with low two-dose MMR coverage — not by the vaccine failing, but by vaccination gaps allowing the virus to find susceptible hosts.

WHO and ECDC issued specific guidance for the approximately 197 passengers and crew aboard MV Hondius following the Andes hantavirus cluster. Recommended actions: (1) Self-monitor daily for fever (>38°C / 100.4°F), severe muscle aches in the thighs, hips, or back, fatigue, or any breathing difficulty for 8 weeks from last potential exposure aboard the ship. (2) If symptoms develop, call emergency services immediately and inform them of your travel on MV Hondius — do not self-drive to an emergency room. Provide the ship's name, dates aboard, and cabin number to the receiving healthcare team. (3) Passengers who disembarked at Saint Helena on 24 April 2026 should have already been contacted by local health authorities; if not, contact your national health authority directly. (4) Normal daily activities including work may continue while asymptomatic — Andes virus is NOT spread through casual contact, shared office air, or public transport. (5) Defer blood donation until 8 weeks after disembarkation. WHO distributed diagnostic kits to all countries known to host former passengers or crew, covering 23 nationalities. Your national traveler health hotline can provide country-specific guidance.

Yes. Smallpox vaccines provide cross-protection against mpox because both viruses are orthopoxviruses. The JYNNEOS vaccine (MVA-BN, Imvamune/Imvanex) is specifically approved for both mpox and smallpox prevention. ACAM2000 (the replication-competent vaccinia vaccine) is also protective but carries more side-effect risks. Pre-1980 smallpox vaccination campaigns conferred approximately 85% protection against mpox; that immunity has waned in the global population since routine vaccination stopped. JYNNEOS is now recommended as a 2-dose series for at-risk individuals in many countries.

Hantavirus is diagnosed using a combination of laboratory tests and clinical criteria. The gold standard for Hantavirus Pulmonary Syndrome (HPS) is serology: IgM and IgG ELISA antibody tests that become positive within days of symptom onset. RT-PCR (reverse-transcription polymerase chain reaction) can detect viral RNA in blood during the early febrile phase before antibodies develop, and was used to confirm Andes virus in the MV Hondius cluster cases. Supportive CBC findings include thrombocytopenia (platelets often below 150,000/µL), immunoblasts (activated lymphocytes), hemoconcentration (rising hematocrit), and left-shifted neutrophilia. Chest X-ray and CT show bilateral interstitial infiltrates as HPS progresses to pulmonary edema. Diagnosis typically combines a compatible clinical picture, recent rodent exposure or travel to an endemic area, and confirmatory serology or PCR. Standard influenza or COVID-19 tests will NOT detect hantavirus — physicians must order specific hantavirus serology panels, available through most state and national reference laboratories in the US, EU, Argentina, and Chile.

The MV Hondius 2026 Andes hantavirus outbreak unfolded over six months across four continents. November 2025–April 2026: Patient Zero travels overland for four months through Argentina, Chile, and Uruguay — the endemic zone for Andes virus — before boarding. April 1, 2026: MV Hondius departs Ushuaia, Argentina with 197 passengers and crew from 23 nationalities. April 6: First passenger develops symptoms; hantavirus not yet suspected. April 11: First fatality — a Dutch passenger dies five days after symptom onset; hantavirus identified retroactively from preserved samples. April 24: 30 passengers disembark at Saint Helena (remote South Atlantic island), triggering a global contact tracing operation across six additional countries. May 4: WHO opens Disease Outbreak News DON599 — the first international alert — confirming a multi-country hantavirus cluster. May 5: Polymarket's 'Hantavirus pandemic 2026' market peaks at 38% probability, with $1.3 million in trading volume. May 7: WHO Director-General states the outbreak is 'not the next COVID'; 5 confirmed cases, 2 deaths confirmed; 2,500 diagnostic kits dispatched to five countries. May 11: MV Hondius arrives Las Palmas de Gran Canaria (Canary Islands, Spain) for final disembarkation of remaining 146 passengers. June 2026: Active contact tracing continues in multiple countries within the 8-week incubation window; total confirmed deaths: 3.

The MV Hondius cluster is the active hantavirus outbreak as of 2026. Live counts (confirmed cases, suspected cases, deaths, affected countries, and people under contact tracing) are shown on the homepage KPI bar and refresh hourly from D1. Patients are hospitalized in the Netherlands, Germany, Switzerland, South Africa, and Saint Helena; contact tracing remains active in the United States, Singapore, Canada, France, the United Kingdom, and Spain. WHO, CDC, ECDC, PAHO, and Africa CDC have each issued situational updates. Prediction markets on Polymarket are tracking the probability of WHO declaring a pandemic in 2026 and additional country-specific case confirmations — see the Markets section for live odds. All numbers update hourly from 50+ sources; this FAQ deliberately avoids hardcoded figures so it never goes stale.

Live counts for the MV Hondius cluster (confirmed cases, suspected cases, deaths, affected countries) are shown on the homepage and refresh hourly from D1. The cluster is unusual not for raw case count but for its multi-country footprint via cruise ship travel — passengers from over 20 nationalities disembarked in multiple ports, requiring international contact tracing. Beyond the Hondius cluster, sporadic background hantavirus cases occur annually in endemic regions: typically 20-40 cases/year in the USA (Sin Nombre), 100-200 in Argentina (Andes), several thousand HFRS cases across Eurasia (Puumala, Hantaan, Seoul).

No. Mpox is not eradicated. Smallpox is the only human disease ever declared eradicated (WHO, 1980), achieved through a global vaccination campaign. Mpox continues to circulate in animal reservoirs (primarily rodents in Central and West Africa) and causes recurrent human outbreaks. The 2022-2024 global mpox outbreak (clade IIb) led the WHO to declare a Public Health Emergency of International Concern (PHEIC) twice: in 2022 and again in August 2024 when clade I expanded in the DRC and neighbouring countries. Eradication of mpox is not currently feasible given its animal reservoir.

The Andes virus (ANDV) is a hantavirus species endemic to southern South America, particularly Argentina, Chile, and parts of Uruguay and Bolivia. It is named after the Andes mountain range, where the long-tailed pygmy rice rat (Oligoryzomys longicaudatus) — its primary natural reservoir — is widely distributed. ANDV causes hantavirus pulmonary syndrome (HPS) with a case fatality rate of 30-40% and is unique among hantaviruses in being capable of limited person-to-person transmission, demonstrated in clusters dating back to a 1996 outbreak in El Bolsón, Argentina. The MV Hondius cluster involves the Andes virus, with the index case having traveled extensively in Argentina, Chile, and Uruguay between November 2025 and April 2026.

Ebola virus disease (EVD) is a severe, often fatal illness caused by viruses of the Ebolavirus genus (family Filoviridae). Six species are known — Zaire, Sudan, Bundibugyo, Taï Forest, Reston, and Bombali ebolavirus — with case-fatality rates historically ranging 25-90% depending on strain and access to care. The natural reservoir is believed to be fruit bats (Pteropodidae); spillover to humans occurs via contact with infected wildlife, then spreads human-to-human through direct contact with blood or body fluids. The active 2026 outbreak in the Democratic Republic of the Congo and Uganda, declared a WHO Public Health Emergency of International Concern on 18 May 2026, is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved.

Hantavirus is a family of RNA viruses (family Hantaviridae) transmitted primarily from rodents to humans. Depending on the species, it causes two distinct syndromes: Hantavirus Pulmonary Syndrome (HPS), marked by severe respiratory failure and 30–40% mortality in the Americas (Andes, Sin Nombre viruses), and Hemorrhagic Fever with Renal Syndrome (HFRS), affecting the kidneys in Eurasia (Hantaan, Puumala, Seoul viruses) with 1–15% mortality. There is no specific antiviral treatment or internationally approved vaccine. Infection occurs mainly through inhalation of aerosolized rodent excreta (urine, droppings, saliva). In 2026, the primary active cluster involves the Andes virus, linked to the MV Hondius cruise ship.

Lassa fever is an acute viral haemorrhagic illness caused by Lassa mammarenavirus (Arenaviridae family). It is endemic in West Africa — primarily Nigeria, Sierra Leone, Liberia, and Guinea — and was first identified in 1969 in Lassa, Nigeria. The disease is a zoonosis: its primary reservoir is the multimammate rat (Mastomys natalensis). Approximately 80% of infections are mild or asymptomatic; the remaining 20% can progress to severe disease involving haemorrhagic manifestations and multi-organ failure.

The MV Hondius departed Ushuaia, Argentina on 1 April 2026 with 197 passengers from 23 countries. The voyage proceeded with WHO and an embedded medical expert overseeing on-board assessment after the initial cases emerged. Disembarkation phases included 30 passengers at Saint Helena on 24 April, individual medical evacuations to South Africa, the Netherlands, Germany, and Switzerland, and final disembarkation in the Canary Islands (Spain). The ship has since departed the Canaries en route to Rotterdam for deep cleaning and disinfection. The live MV Hondius timeline page on this site is updated whenever WHO/CDC/ECDC publish new statements.

The first symptoms of Ebola virus disease appear 2-21 days after exposure (typically 8-10 days) and include abrupt high fever (≥38.6°C/101.5°F), intense headache, severe muscle pain, extreme fatigue, sore throat, and loss of appetite. By days 3-7 a gastrointestinal phase follows, with profuse watery diarrhoea (up to 10 L/day in severe cases), vomiting, abdominal pain, and hiccups. In roughly half of severe cases, a haemorrhagic phase develops around days 5-10 — bleeding from injection sites and mucosal surfaces, and a non-itchy rash on the trunk by day 5-7. A person is not contagious until symptoms begin.

Early hantavirus and flu symptoms overlap: both cause fever, fatigue, muscle aches, and headache. CDC clinical sources note four differentiators. (1) Hantavirus muscle pain is severe and concentrates in large muscle groups (thighs, hips, lower back); flu pain is more diffuse. (2) Hantavirus rarely causes upper respiratory symptoms early on (no runny nose, sore throat); flu commonly does. (3) Hantavirus progresses to rapid respiratory deterioration 4-10 days after onset (HPS phase) — a hallmark not seen in flu. (4) Hantavirus has no seasonal pattern; flu peaks in winter. CDC clinical guidance specifies that a history of rodent exposure or travel to an endemic region is the key information that triggers consideration of hantavirus testing.

Seek emergency care immediately — do not wait — if any of these three warning signs apply: (1) Severe muscle aches (thighs, hips, lower back) with high fever above 38°C (100.4°F), AND a history of rodent contact or rural travel in South America (especially Argentina, Chile, Uruguay) within the past 8 weeks. (2) Progressive shortness of breath or difficulty breathing appearing 4–10 days after a fever begins — this signals the life-threatening cardiopulmonary phase of Hantavirus Pulmonary Syndrome (HPS), which can deteriorate to respiratory failure within hours. (3) Any influenza-like illness if you were a passenger or crew member aboard MV Hondius (2026 Andes virus cluster) within the past 6 weeks — tell the emergency team about your ship itinerary immediately. CDC clinical guidance emphasizes that outcomes improve significantly with early hospitalization, oxygen support, and ICU monitoring before respiratory failure develops. Hantavirus has a 30–40% case fatality rate in HPS — 'it might be the flu' is a dangerous assumption if the exposure risk factors above apply.

Mpox illness typically lasts 2-4 weeks. A prodromal phase of fever, lymphadenopathy, and fatigue precedes the rash by 1-5 days. The rash phase — lesions progressing macule, papule, vesicle, pustule, scab — lasts 2-3 weeks. A person remains infectious from symptom onset until all scabs have fallen off and new skin has healed beneath them. Milder clade IIb cases from the 2022 outbreak (few lesions limited to the genital area) sometimes resolved in under 2 weeks.

Symptoms begin 6-21 days after exposure. Mild cases present with fever, general weakness, headache, sore throat, and mild gastrointestinal symptoms. Severe cases (about 20% of infections) include high fever, chest pain, vomiting, diarrhoea, facial swelling, and haemorrhagic manifestations (bleeding from gums, nose, or eyes). A key late complication is sensorineural hearing loss, occurring in 25-30% of patients — including those who recover from acute illness — and is often permanent.

Measles begins with 3–4 days of high fever (often above 40°C/104°F), cough, runny nose (coryza), and red, watery eyes (conjunctivitis) — known as the '3 Cs'. A key early sign is Koplik's spots: tiny white or grey-blue dots on the inside of the cheeks, appearing 1–2 days before the rash and pathognomonic (unique) to measles. The hallmark maculopapular rash then starts at the hairline and face, spreading downward to the trunk and limbs over 3 days. Fever peaks when the rash appears, then gradually falls if the illness is uncomplicated. Complications include ear infections (about 1 in 10 children), pneumonia (the leading cause of measles deaths), and, rarely, encephalitis (1–2 per 1,000 cases). A lesser-known long-term risk is immune amnesia: measles can wipe out 11–73% of existing antibody memory for 2–3 years, leaving recovered individuals more susceptible to other infections.

Both diseases begin with fever, headache, back pain, and fatigue, followed by a characteristic rash. The key distinguishing features of mpox are: (1) prominent lymphadenopathy (swollen glands) — absent in smallpox; (2) rash lesions may appear in different stages simultaneously; (3) genital/perianal lesions are common in clade IIb. Smallpox lesions were uniform in stage and deeply embedded in the skin. Mpox lesions evolve through macule, papule, vesicle, pustule, scab, typically over 2-4 weeks. In the 2022 clade IIb outbreak, many cases presented with few lesions limited to the genital area without a classical widespread rash.

Hantavirus infection typically presents in two phases (CDC). The early febrile phase, lasting 1-7 days, includes fever, severe muscle aches (thighs, hips, back, shoulders), fatigue, headache, dizziness, chills, and sometimes nausea, vomiting, or abdominal pain. The late cardiopulmonary phase, 4-10 days after onset in HPS cases (Andes, Sin Nombre), brings cough, shortness of breath, fluid in the lungs, and rapidly progressing respiratory failure. HFRS variants (Puumala, Hantaan, Seoul) additionally cause acute kidney injury and bleeding manifestations. The clinical hallmark distinguishing hantavirus from influenza or COVID-19 is the abrupt transition to severe respiratory deterioration in HPS cases.

Survivors of Hantavirus Pulmonary Syndrome (HPS) can make full recoveries, but the critical window is narrow. Once the cardiopulmonary phase begins — typically 4–10 days after symptom onset — patients may deteriorate rapidly from mild dyspnea to full respiratory failure within hours. Early ICU admission with supplemental oxygen, mechanical ventilation, and in severe cases ECMO (extracorporeal membrane oxygenation, heart-lung bypass) is the standard of care and significantly improves survival odds. Most survivors who receive adequate ICU support are discharged within 2–6 weeks. Long-term sequelae: some HPS survivors experience reduced pulmonary function for several months but most regain normal lung capacity within a year. There is no known chronic carrier state for hantavirus — the virus does not persist indefinitely after recovery. Hemorrhagic Fever with Renal Syndrome (HFRS) variants (Puumala, Hantaan) have a better prognosis overall (case fatality 0.1–15%) and renal function typically recovers, though dialysis may be needed acutely. The three deaths in the MV Hondius 2026 cluster occurred before ECMO could be initiated, underscoring that rapid recognition and early ICU transfer are the main modifiable survival factors.

As of May 2026, no hantavirus vaccine has received approval from WHO, FDA, or EMA. South Korea and China have used inactivated hantavirus vaccines domestically (e.g., Hantavax) for HFRS strains (Hantaan, Seoul), but these are not approved internationally and do not protect against the New World HPS strains (Andes, Sin Nombre). Several vaccine candidates targeting Andes and Sin Nombre virus are in early-stage research and Phase 1 trials, but none are expected to reach approval before 2028. The Polymarket question 'Hantavirus vaccine approved in 2026?' currently trades at 2% probability.

For Zaire ebolavirus, yes: Ervebo (rVSV-ZEBOV-GP, Merck) has been FDA/EMA-approved since 2019 and is used in ring vaccination during outbreak response, and two monoclonal antibody therapies — Ebanga (mAb114) and Inmazeb (REGN-EB3) — are FDA-approved and reduce mortality when given early. Sudan ebolavirus vaccine candidates are in advanced trials but not yet WHO-prequalified. Critically, the active 2026 outbreak in the DRC and Uganda is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved — treatment there relies on supportive intensive care (fluids, electrolyte balance, oxygen, blood pressure support).

Ribavirin, an antiviral drug, is effective when given early — ideally within 6 days of fever onset. Early supportive care (IV fluids, electrolyte correction, treating secondary infections) also significantly improves outcomes. Convalescent plasma has been explored but its efficacy is not firmly established. There is currently no WHO-approved vaccine for Lassa fever, though multiple vaccine candidates are in clinical development.

There is no approved specific antiviral drug for measles. Treatment is supportive — meaning it aims to reduce symptoms and prevent complications rather than directly kill the virus. Key elements include: adequate hydration, fever management with acetaminophen or ibuprofen (never aspirin in children), and vitamin A supplementation — WHO recommends two high-dose vitamin A doses for all children with measles, as it has been shown to significantly reduce measles mortality and the severity of complications including blindness and pneumonia. Secondary bacterial infections (the most common cause of measles-related deaths in both children and adults) are treated with appropriate antibiotics. Severe pneumonia and measles encephalitis require hospitalization and may need intensive care. The best 'treatment' remains prevention: two doses of MMR vaccine before exposure provide lifelong protection in ~97% of recipients.

Tecovirimat (TPOXX/ST-246) is an antiviral approved by the FDA and EMA specifically for the treatment of orthopoxvirus infections including mpox. Brincidofovir and cidofovir are alternative antivirals used in severe cases. For most people with clade II mpox, illness is self-limiting and resolves within 2-4 weeks with supportive care (pain management, wound care, hydration). Severe cases — clade I infection, immunocompromised patients, children, or extensive skin involvement — require antiviral treatment and may need hospitalisation.

The two viruses differ on nearly every dimension that matters epidemiologically. Transmission: COVID-19 (SARS-CoV-2) spreads efficiently via airborne respiratory droplets and aerosols between humans; hantavirus is primarily zoonotic (rodent-to-human), with Andes virus the only species showing rare limited human-to-human spread in close prolonged contact. R0 (basic reproduction number): COVID-19 original 2-3, current variants up to 8-15; Andes virus R0 in human-to-human transmission <1, meaning sustained outbreaks are unlikely. Mortality: COVID-19 case fatality rate 0.5-2% population-wide; Andes hantavirus 30-40%. Pandemic potential: COVID-19 caused millions of deaths globally; hantavirus has never caused a pandemic and WHO assesses current risk as low. The current MV Hondius cluster illustrates a contained zoonotic event traced to a single source, not the start of a pandemic — current Polymarket pandemic odds are tracked live on this site.

Hantavirus vs Ebola — 30-40% vs 25-90% mortality, rodent vs fruit-bat reservoir, no vaccine vs Ervebo. 7 key differences and live 2026 case counts. (1) Reservoir: hantavirus is carried by rodents (deer mice, voles); Ebola by fruit bats and non-human primates. (2) Human-to-human transmission: hantavirus rarely (only Andes strain, close prolonged contact); Ebola yes, efficiently via body fluids, drives multi-thousand-case outbreaks. (3) Mortality: hantavirus pulmonary syndrome (HPS) 30-40% (Andes virus); Ebola 25-90% depending on strain — Zaire ebolavirus 50-90% historically. (4) Vaccine: hantavirus has none WHO-approved internationally; Ebola has Ervebo (rVSV-ZEBOV) approved by FDA and EMA since 2019 for Zaire ebolavirus, plus advanced-trial Sudan candidates. (5) Treatment: both rely on supportive intensive care; Ebola additionally has two FDA-approved monoclonal antibody therapies — Inmazeb (REGN-EB3) and Ebanga (mAb114), which dramatically reduce mortality when given early. (6) Major outbreaks: hantavirus Argentina 1996, USA 1993 (Four Corners), and the 2026 MV Hondius cluster currently tracked. Ebola West Africa 2014-2016 (28,600 cases / 11,300 deaths), DRC 2018-2020 (3,470 cases / 2,287 deaths), plus recurring outbreaks in Uganda. (7) Pandemic potential: both have remained regional historically; neither has reached global pandemic status. Track both live: MV Hondius cluster at outbreakwatch.net and Ebola Situation Watch 2026 at outbreakwatch.net/ebola.

Both are African viral haemorrhagic fevers, but they differ significantly. Lassa is caused by an arenavirus, Ebola by a filovirus. Lassa is endemic and causes tens of thousands of cases annually; Ebola causes sporadic large outbreaks. Lassa's overall CFR (~1%) is much lower than Ebola's (25-90%), though hospitalised Lassa patients face higher mortality (~15-25%). Lassa does not spread person-to-person as easily as Ebola. Both require similar PPE for healthcare workers.

Mpox and smallpox are both caused by orthopoxviruses, but they are distinct diseases. Smallpox (Variola virus) was eradicated in 1980 and no longer occurs naturally. Mpox (Monkeypox virus) is an ongoing zoonotic disease, with outbreaks in 2022-2024 (clade IIb, global) and 2024-2025 (clade I, primarily Democratic Republic of Congo). Key clinical difference: mpox causes prominent lymphadenopathy (swollen lymph nodes), which does NOT occur in smallpox. Mpox is significantly less severe: clade II fatality rate is under 1%, while smallpox killed approximately 30% of those infected.

Prediction markets are reasonably calibrated for events with abundant trading and public information, but they have known limitations for novel disease outbreaks. Strengths: they aggregate diverse perspectives and update fast as new data arrives. Limitations for outbreaks: (1) thin liquidity in early outbreak markets — a few traders can move prices substantially. (2) Resolution risk — what counts as an 'official pandemic declaration' may itself be disputed. (3) Information asymmetry — health authorities have private data traders do not. (4) Reflexivity — when markets become news, they can influence the very thing they predict. The Polymarket 'Hantavirus pandemic 2026' market currently exceeds $3.5M in volume: enough liquidity to resist single-trader manipulation, but still volatile and sensitive to WHO statements.

A prediction market is an online marketplace where participants buy and sell shares whose value depends on the outcome of a future event. For yes/no events, a YES share pays $1 if the event happens and $0 otherwise; the current price between $0 and $1 represents the market's aggregate estimate of the probability. For example, if 'Hantavirus pandemic in 2026?' YES shares trade at $0.09, the crowd's estimated probability is 9%. Major prediction markets include Polymarket (crypto-based, global) and Kalshi (regulated US derivatives exchange). They are often used by researchers as forecasting signals for events ranging from elections to disease outbreaks, since aggregating many traders' bets can produce calibrated probabilities. OutbreakWatch displays Polymarket and Kalshi data; we do not facilitate trading.

The 'Hantavirus pandemic in 2026?' market on Polymarket has been one of the most volatile health-related markets of the year. Launched on May 4, 2026, it opened at 3.5%, spiked to 38% on May 5 as initial reports of human-to-human transmission and deaths emerged, then fell back to 9% by May 7 after the WHO Director-General publicly framed the cluster as 'not the next COVID'. Total trading volume has crossed $2.2 million. Movement reflects a real-time crowd assessment of three signals: (1) WHO's risk framing, (2) new case reports outside the original ship cluster, and (3) the 6-week incubation period meaning new cases could still emerge through mid-June 2026. The market resolves on December 31, 2026 — bettors are pricing the entire 8-month tail risk.